If you're looking for safety within the healthcare sector, a top name to consider right now is Abbott Laboratories. For ...

PNC Financial Services Group Inc. lowered its holdings in shares of EchoStar Co. (NASDAQ:SATS – Free Report) by 15.5% during the fourth quarter, according to the company in its most recent Form 13F ...

After Novartis’ Pluvicto shook up iSpot.TV’s monthly rankings of the top TV advertising spenders in pharma to kick off the year, it was back to business as usual in February. AbbVie’s ...

For his work in 2024, AbbVie helmsman Robert Michael—who took over as CEO from Richard Gonzalez on July 1—collected nearly $18.5 million in total pay.

Whales with a lot of money to spend have taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie ABBV we detected 29 trades. If we consider the specifics of each trade ...

Earlier this week, AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research ...

Weight loss drug market projected to reach $130 billion in sales: Bloomberg AbbVie to give Gubra up to $1.875 billion to help develop new drug Nearly 900 million adults worldwide are living with ...

AbbVie was downgraded to "Hold" due to high debt, fluctuating earnings, and declining Humira sales, but the stock outperformed with a 31% return since July 2024. Despite mixed quarterly results ...

Donald Trump’s tariffs have headlined myriad news stories this week—including at BioSpace, where we reported Pfizer CEO Albert Bourla’s claim that his company is prepared to reshore manufacturing if ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.